Mankind Pharma Limited Earnings Summary — Q4 FY2026

\[Image: Im2\]
May 26, 2026

BSE Limited
P J Towers,

Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Investor Conference Call for Q4 & FY26 – Transcript

Ref.: Regulation 30 of Securities and Exchange Board of India (Listing Obligations
and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

Pursuant to Regulation 30 of the Listing Regulations, please find enclosed the transcript of the
Investor Conference Call for Q4 & FY26 held on Wednesday, May 20, 2026 at 12:00 Noon.
(IST).

The transcript is also available on the website of the Company at [www.mankindpharma.com](http://www.mankindpharma.com/).

You are requested to kindly take the same on records.

Thanking You,

For Mankind Pharma Limited

HITESH KUMAR JAIN

KUMAR JAIN

Digitally signed by

Hitesh Kumar Jain
Company Secretary &

Date: 2026.05.26

Company Secretary &
Compliance Officer

Encl.: A/a

* * *

# “Mankind Pharma Limited Q4 FY26 Earnings Conference Call”

# May 20, 2026

## MANAGEMENT: MR. RAJEEV JUNEJA – VICE CHAIRMAN AND MANAGING DIRECTOR

## MR. SHEETAL ARORA – CHIEF EXECUTIVE OFFICER

### AND WHOLE-TIME DIRECTOR

## MR. SUDIPTA ROY – SENIOR PRESIDENT, SALES AND MARKETING

## MR. ARJUN JUNEJA – CHIEF OPERATING OFFICER MR. ASHUTOSH DHAWAN – GLOBAL CHIEF FINANCIAL

## OFFICER MR. PRAKASH AGARWAL – PRESIDENT STRATEGY

## MR. ABHISHEK AGARWAL – HEAD INVESTOR RELATIONS

### Page 1 of 18

* * *

Moderator:

Ladies and gentlemen, good day, and welcome to Mankind Pharma Limited Q4 FY26 Earnings
Conference Call. As a reminder, all participant lines will be in the listen-only mode and there
will be an opportunity for you to ask questions after the presentation concludes. Please note that
this meeting is being recorded.

I now hand the conference over to Mr. Abhishek Agarwal from Mankind Pharma Limited. Thank
you, and over to you, sir.

Abhishek Agarwal:

Good afternoon, everyone. We welcome you to our fourth quarter FY26 earnings call. On call
today we have Mr. Rajeev Juneja, our Vice Chairman and Managing Director; Mr. Sheetal
Arora, Chief Executive Officer and Whole-Time Director; Mr. Arjun Juneja, Chief Operating
Officer; Mr. Sudipta Roy, Senior President, Sales and Marketing; Mr. Ashutosh Dhawan, Global
Chief Financial Officer; and Mr. Prakash Agarwal, President, Strategy.

We will begin today's discussion with Mr. Rajeev Juneja providing quarterly and annual update,
followed by business insights from Mr. Sheetal Arora. Thereafter, Mr. Ashutosh Dhawan will
provide a detailed overview of the financial performance before we move on to the Q&A session.

Please note that statements made on this call that relates to future events or performance are
forward-looking in nature and reflects management current expectations. These statements are
subject to various risks and uncertainties, and actual results may differ materially, and Mankind
does not undertake any obligation to update or revise these statements in the future. A detailed
disclaimer in this regard is included in the investor presentation uploaded on our website.

Now I will hand over to Rajeev sir for his remarks.

Rajeev Juneja:

Thank you, Abhishek, and a very good afternoon to all. Welcome to the quarter 4 and financial
year '26 earnings call. In financial year '26, we made steady progress in strengthening our core
business while continuing our strategic advancements towards specialisation-led growth. Our
focused initiatives towards people, processes and technology, supported by better execution
discipline and capability enhancement are now translating into quarter-on-quarter performance
improvement.

For the financial year 2026, overall domestic revenue increased by 14.4% year-on-year.
Moreover, I would like to highlight that our volume growth has increased to 2.3% in financial
year '26 versus 0.5% last year, led by strate

…